Brickell is focused on the development of novel and differentiated therapies for the treatment of skin diseases.

Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated therapeutics for the treatment of skin diseases. Our current pipeline consists of new molecular entities targeting the treatment of the following indications: hyperhidrosis, atopic dermatitis, contact dermatitis, acne and psoriasis.


Latest News

[November 24, 2015]

Brickell Secures Exclusive WW Rights to Novel Series of RORγ Inhibitors as Potential Topical Therapy for Psoriasis.


[July 8, 2015]

Brickell Announces Appointment of Industry Veterans Dr. Patricia Walker as President and CSO and Dr. Elizabeth Hussey as VP, Product Development


[April 1, 2015]

Brickell Signs Exclusive License and Development Agreement for its novel, topical soft-anticholigenric, BBI-4000, with Kaken Pharmaceutical Co., Ltd. in Japan.